Jin Su-Eon, Jin Hyo-Eon, Hong Soon-Sun
Department of Drug Development, College of Medicine, Inha University, 3-ga, Sinheung dong, Jung-gu, Incheon 400-712, Republic of Korea.
Department of Bioengineering, University of California, Berkeley and Physical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
Biomed Res Int. 2014;2014:814208. doi: 10.1155/2014/814208. Epub 2014 Feb 19.
Targeted delivery systems of nanobiomaterials are necessary to be developed for the diagnosis and treatment of cancer. Nanobiomaterials can be engineered to recognize cancer-specific receptors at the cellular levels and to deliver anticancer drugs into the diseased sites. In particular, nanobiomaterial-based nanocarriers, so-called nanoplatforms, are the design of the targeted delivery systems such as liposomes, polymeric nanoparticles/micelles, nanoconjugates, norganic materials, carbon-based nanobiomaterials, and bioinspired phage system, which are based on the nanosize of 1-100 nm in diameter. In this review, the design and the application of these nanoplatforms are discussed at the cellular levels as well as in the clinics. We believe that this review can offer recent advances in the targeted delivery systems of nanobiomaterials regarding in vitro and in vivo applications and the translation of nanobiomaterials to nanomedicine in anticancer therapy.
为了癌症的诊断和治疗，有必要开发纳米生物材料的靶向递送系统。纳米生物材料可以被设计成在细胞水平上识别癌症特异性受体，并将抗癌药物递送到患病部位。特别是，基于纳米生物材料的纳米载体，即所谓的纳米平台，是靶向递送系统的设计，如脂质体、聚合物纳米颗粒/胶束、纳米缀合物、无机材料、碳基纳米生物材料和仿生噬菌体系统，其直径基于1-100nm的纳米尺寸。在这篇综述中，这些纳米平台的设计和应用在细胞水平以及临床中进行了讨论。我们相信，这篇综述可以提供纳米生物材料靶向递送系统在体外和体内应用方面的最新进展，以及纳米生物材料在抗癌治疗中向纳米医学的转化。
